Cũng muốn có suất Ông ngoại quá

-----

Two mRNA vaccines, BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna), received Emergency Use Authorization from the US Food and Drug Administration. Despite high efficacy (tính có hiệu quả, hiệu lực) and few adverse events found in clinical trials (thử nghiệm lâm sàng), only 56% of individuals in the US reported wanting to receive the vaccine.1 One of the reasons for vaccine hesitancy (do dự) is the potential negative effect on fertility (khả năng sinh sản).2 Because reproductive toxicity (đặc tính độc, độ độc) was not evaluated in the clinical trials and SARS-CoV-2 has been associated with decreases in sperm (tinh trùng) parameters (thông số),3 we assessed sperm parameters before and after mRNA vaccine administration.

Men were prescreened to ensure they had no underlying fertility issues. Those with COVID-19 symptoms or a positive test result within 90 days were excluded. Participants provided a semen sample after 2 to 7 days of abstinence (kiêng cữ, kiêng khem, không làm tình), prior to receiving the first vaccine dose and approximately 70 days after the second. Semen analyses were performed by trained andrologists per World Health Organization guidelines and included semen volume, sperm concentration (độ đặc), sperm motility (có thể vận động, di động), and total motile sperm count (TMSC).4 Individuals with oligospermia (ít tinh trùng) (sperm concentration <15 million/mL) were included.

Results

Between December 17, 2020, and January 12, 2021, 45 men volunteered (median age, 28 years [IQR, 25-31]); follow-up samples were obtained at a median of 75 days (IQR, 70-86) after the second dose. The study ended on April 24, 2021. Baseline samples were obtained after a median abstinence period of 2.8 days (IQR, 2-3) and follow-up samples after a median of 3 days (IQR, 3-4). Of the 45 men, 21 (46.7%) received BNT162b2 and 24 (53.3%) received mRNA-1273. Baseline median sperm concentration and TMSC were 26 million/mL (IQR, 19.5-34) and 36 million (IQR, 18-51), respectively. After the second vaccine dose, the median sperm concentration significantly increased to 30 million/mL (IQR, 21.5-40.5; P = .02) and the median TMSC to 44 million (IQR, 27.5-98; P = .001). Semen volume and sperm motility also significantly increased